L&S Knock-Out 5CV 16.06.2025/ DE000LX4M5M9 /
2024-10-31 10:58:18 PM | Chg.-0.05 | Bid10:58:18 PM | Ask10:58:18 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.48EUR | -9.43% | 0.48 Bid Size: - |
0.56 Ask Size: - |
CUREVAC N.V. O.N. | 2.25 EUR | 2025-06-16 | Call |
GlobeNewswire
08-26
Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences
GlobeNewswire
2022-03-25
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA...
GlobeNewswire
2022-01-13
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration o...
GlobeNewswire
2022-01-11
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply ...
GlobeNewswire
2021-12-17
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatme...
GlobeNewswire
2021-12-07
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutation...
GlobeNewswire
2021-12-02
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV...
GlobeNewswire
2021-11-17
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COV...
GlobeNewswire
2021-11-12
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovim...
GlobeNewswire
2021-07-28
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19...
GlobeNewswire
2021-06-21
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for...